Humacyte

Update in progress

HUMA (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Humacyte, Inc. and its subsidiaries develop and manufacture off-the-shelf, implantable, bioengineered human tissues. Using a proprietary platform, it engineers human acellular vessels (HAVs) that aim to be implanted without foreign body response or immune rejection. Its HAV portfolio targets vascular repair, trauma, hemodialysis access, peripheral arterial disease, pediatric heart surgery, CABG, and cellular-therapy delivery (e.g., islet cell transplantation for Type 1 diabetes). Founded 2004, based in Durham, NC.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.24; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive